Editorial Policy

What we prioritize

• Peer-reviewed human clinical studies when available.
• FDA labels, prescribing information and regulatory filings.
• Clinical trial protocols and manufacturer trial summaries.
• Preclinical evidence only when human evidence is limited.
• Clear status labels for approved, investigational and research-only compounds.

How we handle weak evidence

Many peptides are marketed far ahead of the data. When evidence is animal-only, mechanistic or cosmetic, we say that directly. We do not present preclinical findings as proof of human benefit.

Affiliate links

Some pages contain affiliate links. Affiliate relationships do not determine our evidence ratings, regulatory status labels or safety language. See the full affiliate disclosure.

How we review research vendors

Vendor reviews use dated, source-linked checks of public catalogs, product pages, shipping terms and vendor-hosted laboratory documents. We record the product, lot, named laboratory, report date and test result when those details are visible.

We distinguish what PeptideStat directly inspected from what a vendor or laboratory document claims. Unless a review says otherwise, PeptideStat has not purchased the product, collected the sample or commissioned the laboratory analysis. A published COA is a documentation signal, not proof that every vial matches the report or is suitable for human use.

Updates and corrections

We update pages when major trials, approvals, safety actions or product changes materially affect the content. To report an issue, email admin@peptidestat.com.

Who writes PeptideStat

Guides are published by the PeptideStat Editorial Team, with source-first review for medical and research claims.